On cost grounds, National Institute for Health and Care Excellence is planning to block a new cancer drug which can increase a breast cancer patient’s life span by six months.
New Method Of Delivering Chemotherapy
Chemotherapy often leaves cancer patients feeling sick and with a number of other side effects. For some people with advanced cancer, the treatment
Chemotherapy often leaves cancer patients feeling sick and with a number of other side effects. For some people with advanced cancer, the treatment
Activists are urging the drug company to lower the price of the new breast cancer medicine. Nice chief executive Sir Andrew Dillon said, “We had hoped that Roche would have recognised the challenge the NHS faces. We apply as much flexibility as we can in approving new treatments, but the reality is that given its price and what it offers to patients, it will displace more health benefit which the NHS could achieve in other ways than it will offer to patients with breast cancer.”
The drug is specially meant for women with HER2-receptor-positive cancer that has spread around the body. The drug kills cancerous cells from within. It is unlikely to cause side effects such as hair loss, noticed with many other types of chemotherapy.
Breast Self Examination
Slides and animation of Breast Self Examination for early detection of breast cancer lumps in women
Slides and animation of Breast Self Examination for early detection of breast cancer lumps in women
If the cost of the drug is not brought down, Kadcyla will be the third breast cancer drug made by Roche to be rejected by Nice due to its cost. And if the decision is finalised this year, patients in England will not be given the drug by the NHS.
Advertisement
New Method for Efficiently Transporting Antibodies Across the Blood-Brain Barrier Reported by Roche
Results on the technology that efficiently transfers investigational antibodies from the blood through the blood-brain barrier into the brain in preclinical models have been published.
Results on the technology that efficiently transfers investigational antibodies from the blood through the blood-brain barrier into the brain in preclinical models have been published.
NHS Sight Tests Lead to Waste Due to Referrals With Insignificant Abnormalities
Apart from trauma and orthopedics, ophthalmology receives more NHS outpatient referrals than any other specialty, says Michael Clarke, Consultant Ophthalmologist at Newcastle Eye Centre
Apart from trauma and orthopedics, ophthalmology receives more NHS outpatient referrals than any other specialty, says Michael Clarke, Consultant Ophthalmologist at Newcastle Eye Centre
